CD4(+) T cell-licensed CD8(+) T cells are required for immunotherapy response in MHC-I negative MMRd cancer.
Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.